Aurinia Pharmaceuticals Inc.
HealthcareNASDAQ:AUPH · NASDAQ Global Market
-$0.03 today
Vol 0.67M · Avg 1.28M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $287.2M +4893.1% | $5.8M +107.4% | -$78.0M +27.9% | -$108.2M +40.2% | -$181.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $9.3M -52.3% | $19.4M +67.0% | $11.6M +330.4% | $2.7M -2.0% | $2.8M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$176.2M | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $14.7M -53.5% | $31.6M -30.3% | $45.3M +40.3% | $32.3M +3.4% | $31.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$8.8M -261.2% | $5.4M +197.1% | -$5.6M +17.7% | -$6.8M +68.5% | -$21.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$4.9M +60.6% | -$12.5M -17.4% | -$10.6M -650.4% | $1.9M +112.5% | -$15.4M | $592.6M | $1.3B | $626.2M |
| Inventory | -$6.5M -1454.7% | $477.0K +103.0% | -$15.9M -74.9% | -$9.1M -60.7% | -$5.6M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$1.9M -317.9% | $860.0K -30.6% | $1.2M +256.6% | -$792.0K -119.4% | $4.1M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $4.5M -73.1% | $16.6M -15.6% | $19.6M +1652.4% | $1.1M +124.1% | -$4.7M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $9.5M +153.1% | -$17.9M -162.9% | -$6.8M -1569.9% | $462.0K -95.8% | $10.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $135.7M +205.6% | $44.4M +232.7% | -$33.5M +57.9% | -$79.5M +49.6% | -$157.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$252.0K +10.3% | -$281.0K +60.9% | -$718.0K -145.9% | -$292.0K +80.5% | -$1.5M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 +100.0% | -$1.2M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$526.6M +3.5% | -$545.8M -4.3% | -$523.5M +0.1% | -$524.0M -19.4% | -$439.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $494.1M -15.6% | $585.4M +10.6% | $529.4M +14.0% | $464.3M +31.0% | $354.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 +100.0% | -$43.0K +99.6% | -$11.9M -1689.4% | -$663.0K +96.0% | -$16.6M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$32.8M -183.5% | $39.3M +685.5% | -$6.7M +88.9% | -$60.6M +41.6% | -$103.9M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$13.1M -9.6% | -$12.0M -19.6% | -$10.0M | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $14.9M | $0 | $0 | $0 -100.0% | $196.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$98.2M -143.9% | -$40.2M | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$9.8M -411.4% | $3.1M -35.9% | $4.9M +101.2% | $2.4M -90.0% | $24.4M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$106.1M -116.1% | -$49.1M -857.0% | -$5.1M -310.9% | $2.4M -98.9% | $221.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$3.2M -109.3% | $34.6M +176.3% | -$45.3M +67.1% | -$137.7M -240.5% | -$40.5M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $135.4M +207.0% | $44.1M +229.0% | -$34.2M +57.2% | -$79.8M +49.9% | -$159.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.86B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Immunocore Holdings plc
NASDAQ:IMCR
$1.47B
Biohaven Ltd.
NYSE:BHVN
$1.19B
MannKind Corporation
NASDAQ:MNKD
$1.13B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
SEC Filings
Recent regulatory filings
No filings found.
Does AUPH generate free cash flow?
Aurinia Pharmaceuticals Inc. (AUPH) generated $135.41M of free cash flow in fiscal 2025.
How much operating cash flow does AUPH produce?
Operating cash flow was $135.66M, before capital expenditures of $252,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.